Announced
Financials
Tags
Acquisition
United States
generic pharmaceuticals
pharmaceutical company
Pending
Single Bidder
Pharmaceuticals
Cross Border
Majority
Private
Friendly
Synopsis
Dr. Reddy's Laboratories, a global pharmaceutical company headquartered in Hyderabad, India, agreed to acquire the US perscription unit of Mayne Pharma, an ASX-listed specialty pharmaceutical company, for $105m. "The US has always been an important market for us. The portfolio of products acquired from Mayne Pharma is a strategic fit with our growth objectives. The portfolio includes some high entry-barrier products. It also complements our existing portfolio by introducing products focused on women’s health. Our strong balance sheet enables us to acquire products of strategic importance to strengthen our base business and build for long-term growth," Erez Israeli, Dr. Reddy’s CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.